Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis

被引:31
|
作者
Saad, F [1 ]
McKiernan, J
Eastham, J
机构
[1] Univ Montreal, Ctr Hosp, Hop Notre Dame, Montreal, PQ, Canada
[2] Columbia Univ, New York, NY 10032 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
关键词
bisphosplionates; prostate cancer; hormone sensitive; bone metastases; bone loss;
D O I
10.1016/j.urolonc.2005.06.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Men with prostate cancer are at risk for bone loss and skeletal complications throughout the course of their disease. Bone loss is prevalent in many men with prostate cancer at initial diagnosis, and initiating androgen deprivation therapy results in accelerated bone resorption, leading to bone loss and an increased risk of fracture. These men are also at high risk for disease progression and bone metastases that can result in significant skeletal morbidity, including pathologic fracture, spinal cord compression, and debilitating bone pain requiring additional therapy. Excessive osteoclast activity plays a central role in the pathophysiology of bone disease at each stage of prostate cancer disease progression. Zoledronic acid, a highly potent inhibitor of osteoclast-mediated bone resorption, has increased bone mineral density in men receiving androgen deprivation therapy and is the only bisphosphonate that has shown statistically significant reductions in skeletal morbidity in patients with bone metastases from prostate cancer. Furthermore, preclinical evidence suggests that zoledronic acid has antitumor activity in prostate cancer models. Recently, a treatment algorithm was developed by the 3rd International Consultation on Prostate Cancer recommending the use of zoledronic acid for the prevention of skeletal complications in patients with bone metastases from prostate cancer, regardless of their hormone status, and for the prevention of treatment-induced bone loss in patients without evidence of bone metastases. According to this algorithm, zoledronic acid should be considered for the prevention of skeletal morbidity in patients with prostate cancer throughout their treatment continuum. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:4 / 12
页数:9
相关论文
共 50 条
  • [31] First-line therapy for metastatic hormone-sensitive prostate cancer
    Rexer, Heidrun
    Feyerabend, Susan
    Graefen, Markus
    AKTUELLE UROLOGIE, 2023, 54 (03) : 186 - 188
  • [32] Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer Reply
    McManus, Hannah D.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3874 - +
  • [33] Chemohormonal therapy for metastatic hormone-sensitive prostate cancer: An Asian perspective
    Teoh, Jeremy Yuen-Chun
    Ng, Chi-Fai
    Poon, Darren Ming-Chun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 5 - 8
  • [34] Management of hormone-sensitive metastatic prostate cancer - Update on hormonal therapy
    Figg, WD
    Feuer, JA
    Bauer, KS
    CANCER PRACTICE, 1997, 5 (04) : 258 - 263
  • [35] Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer
    Daniel E. Lage
    M. Dror Michaelson
    Richard J. Lee
    Joseph A. Greer
    Jennifer S. Temel
    Christopher J. Sweeney
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 1181 - 1188
  • [36] Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer
    Lage, Daniel E.
    Michaelson, M. Dror
    Lee, Richard J.
    Greer, Joseph A.
    Temel, Jennifer S.
    Sweeney, Christopher J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 1181 - 1188
  • [37] Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer
    Borque-Fernando, A.
    Perez-Fentes, D. A.
    Rodrigo-Aliaga, M.
    Puente-Vazquez, J.
    Gomez-Iturriaga, A.
    Unda, M.
    Calleja-Hernandez, M. A.
    Cozar-Olmo, J. M.
    alvarez-Ossorio, J. L.
    ACTAS UROLOGICAS ESPANOLAS, 2024, 48 (10): : 703 - 717
  • [38] Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy
    Serritella, Anthony V.
    Hussain, Maha
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (03) : 293 - 312
  • [39] Zoledronic acid reduces bone resorption in patients with hormone prostate cancer
    Drudge-Coates, L.
    Rajbabu, K.
    Walsh, K.
    Thompson, P. M.
    Muir, G.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 98 - 98
  • [40] Rezvilutamide for metastatic hormone-sensitive prostate cancer
    Singh, Kirti
    Mandal, Swarnendu
    Nayak, Prasant
    Das, Manoj
    Tripathy, Sambit
    LANCET ONCOLOGY, 2022, 23 (11): : E490 - E490